Retirement Systems of Alabama Decreases Holdings in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Retirement Systems of Alabama decreased its holdings in Integra LifeSciences Holdings Co. (NASDAQ:IART) by 3.7% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 85,182 shares of the life sciences company’s stock after selling 3,247 shares during the period. Retirement Systems of Alabama’s holdings in Integra LifeSciences were worth $3,710,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Deerfield Management Company L.P. Series C purchased a new stake in shares of Integra LifeSciences during the third quarter valued at approximately $43,034,000. Assenagon Asset Management S.A. bought a new position in shares of Integra LifeSciences during the third quarter valued at about $25,443,000. Victory Capital Management Inc. boosted its holdings in shares of Integra LifeSciences by 19.5% during the third quarter. Victory Capital Management Inc. now owns 1,465,115 shares of the life sciences company’s stock worth $55,953,000 after purchasing an additional 238,816 shares during the period. Kestrel Investment Management Corp purchased a new position in Integra LifeSciences during the 3rd quarter valued at about $4,676,000. Finally, Cooke & Bieler LP lifted its holdings in Integra LifeSciences by 4.4% in the 4th quarter. Cooke & Bieler LP now owns 2,834,604 shares of the life sciences company’s stock worth $123,447,000 after buying an additional 120,410 shares during the period. Institutional investors own 84.78% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the company. Citigroup upgraded Integra LifeSciences from a “sell” rating to a “neutral” rating and set a $38.00 target price for the company in a report on Wednesday, April 3rd. JMP Securities reduced their price target on shares of Integra LifeSciences from $49.00 to $40.00 and set a “market outperform” rating on the stock in a research report on Tuesday. Bank of America lowered their price objective on shares of Integra LifeSciences from $42.00 to $26.00 and set an “underperform” rating for the company in a report on Tuesday. Morgan Stanley reduced their target price on Integra LifeSciences from $37.00 to $24.00 and set an “underweight” rating on the stock in a report on Tuesday. Finally, Oppenheimer cut Integra LifeSciences from an “outperform” rating to a “market perform” rating in a research note on Tuesday. Three analysts have rated the stock with a sell rating, six have issued a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $36.80.

Integra LifeSciences Trading Up 8.4 %

Integra LifeSciences stock opened at $25.08 on Wednesday. Integra LifeSciences Holdings Co. has a 12 month low of $22.36 and a 12 month high of $51.12. The company has a current ratio of 3.45, a quick ratio of 2.18 and a debt-to-equity ratio of 0.94. The business’s fifty day simple moving average is $32.95 and its two-hundred day simple moving average is $38.24. The company has a market capitalization of $1.97 billion, a price-to-earnings ratio of 30.22, a price-to-earnings-growth ratio of 0.87 and a beta of 1.17.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings data on Monday, May 6th. The life sciences company reported $0.55 EPS for the quarter, meeting the consensus estimate of $0.55. The company had revenue of $368.90 million for the quarter, compared to the consensus estimate of $361.96 million. Integra LifeSciences had a net margin of 4.39% and a return on equity of 15.19%. Integra LifeSciences’s revenue for the quarter was down 3.2% on a year-over-year basis. During the same period in the prior year, the firm posted $0.74 EPS. As a group, equities analysts predict that Integra LifeSciences Holdings Co. will post 3.19 earnings per share for the current fiscal year.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.